Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.55 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.54 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FES | P07332 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.44 |
| ▸ | FRK | P42685 | 1/20 | 0.44 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.44 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406354 | 0.89 | TYK2 (0.58) | PIK3CAPIK3CBPIK3CGTYK2SYK | |
| SCHEMBL3552326 | 0.83 | PIK3CA (0.65) | PIK3CAPIK3CBPIK3CGTYK2SYK | |
| SCHEMBL3558706 | 0.80 | PIK3CB (0.59) | PIK3CAPIK3CBPIK3CDKDM4EHTT | |
| SCHEMBL4133831 | 0.79 | PIK3CA (0.72) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL1309502 | 0.79 | HTT (0.56) | PIK3CAPIK3CBPIK3CGPIK3CDKDM4E | |
| SCHEMBL3554877 | 0.79 | PIK3CB (0.57) | PIK3CAPIK3CBPIK3CDHTT | |
| SCHEMBL3550609 | 0.78 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CGTYK2SYK | |
| SCHEMBL1617732 | 0.76 | TYK2 (0.61) | PIK3CAPIK3CBPIK3CGTYK2SYK | |
| SCHEMBL3560364 | 0.76 | KDM4E (0.53) | TYK2IRAK4KDM4EALDH1A1HTT | |
| SCHEMBL25593999 | 0.74 | ALDH1A1 (0.57) | PIK3CAPIK3CBKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042810-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | PIK3CA 1/4885PIK3CB 10/4885PIK3CG 15/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PIK3CA 137/4885PIK3CB 377/4885PIK3CG 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.